Euphrates Vascular (formerly Pulse Therapeutics) develops magnetic technologies for healthcare applications, currently in the realm of stroke. Pulse Therapeutics has developed a breakthrough medical device designed to significantly increase the effectiveness of the clot-busting drug tPA for the emergency department (ED) based treatment of ischemic stroke.

In 2010, Pulse concluded pre‐clinical studies which demonstrated that intravenously-administered biocompatible iron particles, when controlled by a compact external magnet, substantially accelerate the diffusion of chemical agents in a user-selected direction. This 100% mechanical action is accomplished without the need to attach the drug to the magnetic particles.

The Company believes that its proprietary technology will allow tPA to reach the clot more quickly and at higher concentrations, resulting in a dramatically faster dissolution of the clot as compared to standard IV-tPA delivery.

In 2019 Euphrates Vascular was created via the merger between Pulse Therapeutics and ICHOR Vascular.